It’s all about to happen. But until it happens, then no money should be made waiting for it. We have to see its success to invest in it. Otherwise, the heck with it. There. That had been the bear case against artificial intelligence, generative AI, accelerated computing and large language …
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, Dec. 11, 2023. Brendan McDermid | Reuters Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! A highly popular group of weight loss and …
The injectable weight-loss medication Wegovy is available at New City Halstead Pharmacy on April 24, 2024 in Chicago, Illinois. Scott Olson | Getty Images Novo Nordisk and Eli Lilly have long dominated the rapidly growing weight loss drug market, but their duopoly is closer than ever to facing a threat …
Eli Lilly chief information and digital officer Diogo Rau was recently involved in some experiments in the office, but not the typical drug research work that you might expect to be among the lab tinkering inside a major pharmaceutical company. Lilly has been using generative AI to search through millions …
Is the stock market rally here to stay after April’s terrible month? With the Fed, Apple earnings and the jobs report passing with flying colors this week, the runway to more gains looks a lot less cluttered. The main economic update came Friday in the form of a weaker-than-expected April …
As investors say farewell to a week marked by a Federal Reserve meeting, surprise labor market data and the latest corporate earnings, they’re left trying to figure out what it all means for a stock market that’s still deciding where it wants to go. All three of the major market …
Eli Lilly ‘s raised guidance stole the show Tuesday, offsetting mixed first-quarter results and propelling shares higher by nearly 6%. The numbers leave little doubt that the long-term Eli Lilly success story remains intact, as demand for its new diabetes and obesity drugs, Mounjaro and Zepbound, outstrips supply. Revenue in …
The major U.S. stock indexes closed higher for the week, with the S & P 500 and Nasdaq Composite breaking multiweek losing streaks. Earnings drove the action, despite some less-than-ideal macroeconomic reports on economic growth and inflation. Meta Platforms ‘ report gave the market a bit of a scare Wednesday …
Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. Hollie Adams | Reuters European Union drug regulators found no evidence that highly popular weight loss and diabetes drugs such as Wegovy and Ozempic are linked to an increased risk of suicidal …
The coronal view of a human brain of a patient suffering from Parkinson’s disease Sherbrooke Connectivity Imaging Lab | Getty Images A highly popular class of drugs for diabetes and obesity is showing early potential to help patients with Parkinson’s disease, too. An older diabetes treatment called lixisenatide helped slow …
